Catalog No.
DHJ63101
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
SGRF, IL-23-A, IL-23 subunit alpha, Interleukin-23 subunit p19, IL23A, Interleukin-23 subunit alpha, IL-23p19
Concentration
5.1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NPF7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BI 655066, risankizumab-rzaa, CAS: 1612838-76-2
Clone ID
Risankizumab
Risankizumab for the treatment of psoriasis, PMID: 31460804
Risankizumab: First Global Approval, PMID: 31098898
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis, PMID: 32632826
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis, PMID: 30518998
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis, PMID: 28423301
Risankizumab for psoriasis, PMID: 32346218
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial, PMID: 32594522
Risankizumab in the treatment of psoriasis - literature review, PMID: 31462831
Update on risankizumab for the treatment of moderate to severe psoriasis, PMID: 32933320
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials, PMID: 30097359
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study, PMID: 30056030
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial, PMID: 31280967
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review, PMID: 32427307
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials, PMID: 31583255
Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab, PMID: 30578873
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study, PMID: 28411872
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial, PMID: 32267471
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients, PMID: 31758502
A drug safety evaluation of risankizumab for psoriasis, PMID: 32100591
Risankizumab, PMID: 31145575
Risankizumab in moderate-to-severe plaque psoriasis, PMID: 31578912
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials, PMID: 33052382
Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies, PMID: 32320088
Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial, PMID: 31237727
Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature, PMID: 32510689
Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta-analysis, PMID: 33140468
Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis, PMID: 32158251
Risankizumab for the treatment of moderate to severe psoriasis, PMID: 30462554
Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine, PMID: 31720558
Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective study, PMID: 32761740
Antibodies to watch in 2020, PMID: 31847708
Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal, PMID: 30632140
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date, PMID: 30519540
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis, PMID: 31672037
Efficacy of in-class interleukin-23 inhibitor switching: risankizumab following guselkumab failure in moderate-to-severe psoriasis treatment, PMID: 32998185
Risankizumab for psoriasis, PMID: 30097360
Risankizumab (Skyrizi) for psoriasis, PMID: 31170118
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics, PMID: 30772098
Pharmacoeconomic Review Report: Risankizumab (Skyrizi): (AbbVie) [Internet], PMID: 31876996
Risankizumab: How to choose the right dose in clinical practice?, PMID: 33021745
Risankizumab, PMID: 34251778
Romosozumab-aqqg, upadacitinib, and risankizumab-rzaa, PMID: 31735342
Risankizumab-Aggravated Crusted Scabies in a Patient with Down Syndrome, PMID: 32378153
Risankizumab as a promising therapeutic approach in obese patients, PMID: 32196833
New Treatment Addressing the Pathogenesis of Psoriasis, PMID: 33050592
Acrodermatitis continua Hallopeau successfully treated by risankizumab, PMID: 33368238
Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal, PMID: 31899817
Clinical Review Report: Risankizumab (Skyrizi): (AbbVie) [Internet], PMID: 31393686
Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis, PMID: 32022825
Risankizumab: a game changer in Crohn's disease?, PMID: 30056029
For research use only. Not for human or drug use.
